Form 483

BioReliance Corporation Form 483, 2026-01-29

FDA issued a Form 483 to BioReliance Corporation on 2026-01-29 with 2 public-safe observations.

483· Form 483 issuedHuman Drugs2 observations

BioReliance Corporation · Rockville, United States · Issued January 29, 2026

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

29 Jan 2026
21 CFR 58.33(a)

Study director: follow study protocol

Cited by David L Chon

29 Jan 2026
21 CFR 58.33(c)

Study director: unforeseen circumstances

Cited by David L Chon

Inspected site

BCBioReliance CorporationRockville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 58.33(a)Cited across public-safe Form 483 observations1x
21 CFR 58.33(c)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 2 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere